[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.142.229. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 592
Citations 0
Correction
January 23/30, 2013

Incorrect Residual Heparin Amount in: Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction: The TIME Randomized Trial

JAMA. 2013;309(4):343. doi:10.1001/jama.2012.196454

Incorrect Residual Heparin Amount: In the Original Contribution entitled “Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction: The TIME Randomized Trial,” published in the December 12, 2012, issue of JAMA (2012;308[22]:2380-2389), under the Results heading, third full paragraph, the third sentence should have stated, “The cell product was devoid of significant red blood cell contamination, contained only minuscule amounts of heparin (estimated at 0.01 U/mL), and most participants were infused within 1 hour of completion of cell processing,11 thereby avoiding concerns recently expressed in the literature.12,13” This article has been corrected online.

×